Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?
Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.
Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?
LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.
Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Kexing Biopharm leans on IQVIA as biosimilar competition moves from China to global markets
Biosimilars need speed, but regulators still demand proof. IQVIA and Kexing test whether AI can cut friction without cutting evidence.
Could LANGLARA finally crack the high-cost insulin access problem in the United States?
Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.
Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.
Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption
Samsung Bioepis presented new SB16 subgroup data at WCO 2026. Read what it means for Obodence adoption, biosimilar trust, and osteoporosis care.
What AEON Biopharma Inc.’s analytical strategy reveals about the future of botulinum toxin biosimilars
AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.
Early-stage biosimilar deal between Samsung Bioepis and Sandoz covers vedolizumab and four undisclosed molecules
Samsung Bioepis and Sandoz expand their biosimilar partnership to cover vedolizumab SB36 and four early-stage candidates. What this means for the IBD biologics market.
FDA clears mAbxience–Amneal denosumab biosimilars, opening a new front in osteoporosis and oncology pricing
mAbxience and Amneal Pharmaceuticals have secured U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars, Boncresa and Oziltus, referencing Prolia and XGEVA respectively, clearing a long-anticipated regulatory hurdle in osteoporosis and oncology supportive care. The approvals position Amneal Pharmaceuticals as the exclusive U.S. commercial partner, with mAbxience responsible for development and manufacturing, marking […]